

# Accepted Manuscript

Title: Epstein-Barr Virus Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation

Author: Li Liu, Xuyan Zhang, Sizhou Feng

PII: S1083-8791(18)30115-0

DOI: <https://doi.org/10.1016/j.bbmt.2018.02.026>

Reference: YBBMT 55056


To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 11-1-2018

Accepted date: 26-2-2018

Please cite this article as: Li Liu, Xuyan Zhang, Sizhou Feng, Epstein-Barr Virus Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation, *Biology of Blood and Marrow Transplantation* (2018), <https://doi.org/10.1016/j.bbmt.2018.02.026>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



# Epstein-Barr virus related post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation

Li Liu<sup>1</sup>, Xuyan Zhang<sup>2</sup>, Sizhou Feng<sup>1\*</sup>

**Affiliation of authors:** <sup>1</sup>Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, 300020.

<sup>2</sup>Affiliated Bao'an Hospital of Southern Medical University, Shenzhen, Guangdong, China, 518000.

**\*Corresponding author:** Sizhou Feng, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, 300020. Tel: +86-022-23909162. Email: [szfeng@ihcams.ac.cn](mailto:szfeng@ihcams.ac.cn)

**Conflict of interest:** The authors have no other affiliations or financial involvement with any organization or entity apart from those disclosed. And the authors have no financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

**Financial Support:** This work was funded by the special fund of clinical research of the Chinese Medical Association (Grant number: 16010130629) and CAMS Initiative for Innovative Medicine (Grant number: 2016-12M-1-017).

## Highlights

- EBV-PTLDs are rare but potentially fatal complications of allo-HSCT, characterized by uncontrolled proliferation of EBV-infected lymphocytes.
- The most frequent risk factors include T cell depletion of graft (including ATG use), HLA mismatch, severe GVHD, EBV sero-mismatch (recipient-/donor+) and so on.
- EBV-PTLDs commonly manifest as fever and lymphadenopathy and may rapidly progress to multi-organ failure and even death.
- Histopathological evidences are indispensable for the diagnosis while EBV-DNAemia and imaging abnormalities are also very helpful.
- The management of EBV-PTLDs includes prophylaxis, pre-emptive treatment and targeted therapy. Approaches such as RI, administration of rituximab, DLI, EBV-CTLs and chemotherapy are the common treatment choices, and rituximab based regimen is the mainstay.

**Abstract:** Epstein-Barr virus related post-transplant lymphoproliferative disorders (EBV-PTLDs) are rare but potentially fatal complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT), characterized by uncontrolled proliferation of EBV-infected lymphocytes. The most frequent risk factors include T cell depletion of graft, HLA mismatch, severe graft versus host disease (GVHD), EBV sero-mismatch (recipient-/donor+) and so on.

Download English Version:

<https://daneshyari.com/en/article/8429684>

Download Persian Version:

<https://daneshyari.com/article/8429684>

[Daneshyari.com](https://daneshyari.com)